WO2003005952A2 - Compositions et procedes destines a l'administration de proteines et d'adjuvants encapsules dans des microspheres - Google Patents

Compositions et procedes destines a l'administration de proteines et d'adjuvants encapsules dans des microspheres Download PDF

Info

Publication number
WO2003005952A2
WO2003005952A2 PCT/US2002/021758 US0221758W WO03005952A2 WO 2003005952 A2 WO2003005952 A2 WO 2003005952A2 US 0221758 W US0221758 W US 0221758W WO 03005952 A2 WO03005952 A2 WO 03005952A2
Authority
WO
WIPO (PCT)
Prior art keywords
protein
microspheres
adjuvant
mpl
encapsulated
Prior art date
Application number
PCT/US2002/021758
Other languages
English (en)
Other versions
WO2003005952A3 (fr
Inventor
Mark E. Johnson
Jay T. Evans
Jeffrey A. Kern
Original Assignee
Corixa Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corporation filed Critical Corixa Corporation
Priority to AU2002354644A priority Critical patent/AU2002354644C1/en
Priority to JP2003511761A priority patent/JP2005514326A/ja
Priority to EP02752243A priority patent/EP1417236A4/fr
Priority to NZ530315A priority patent/NZ530315A/en
Priority to CA002452382A priority patent/CA2452382A1/fr
Publication of WO2003005952A2 publication Critical patent/WO2003005952A2/fr
Publication of WO2003005952A3 publication Critical patent/WO2003005952A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Definitions

  • the invention relates to formulations, compositions and methods that can be used for the delivery of vaccines and adjuvants. More particularly, the invention relates to microspheres and methods for preparing microspheres that enable more efficient and effective delivery of protein vaccines and adjuvants.
  • New vaccines are in development for the prevention, as well as the treatment, of cancers and chronic infectious diseases.
  • the most effective vaccines will likely elicit CTL responses in addition to T-helper responses and antibodies.
  • An attractive mode of vaccine delivery is via encapsulation in microspheres. Due to the insolubility of most proteins in organic media, however, microspheres encapsulating proteins typically need to be made by a double-emulsion method. Microsphere formulations made by double- emulsion methods often have undesirable release kinetics (e.g., high initial burst and/ or very slow additional release over time), as indicated by in vitro release studies.
  • the invention provides a composition comprising an adjuvant encapsulated in biodegradable polymeric microspheres and a pharmaceutically acceptable carrier.
  • a protein is co-encapsulated with the adjuvant in the microspheres.
  • the protein comprises an antigen associated with cancer, autoimmune disease or infectious disease.
  • proteins and adjuvants can be delivered via encapsulation in polymeric microspheres either via co-encapsulation in the same microspheres, or co-administered as encapsulated protein in a first set of microspheres and encapsulated adjuvant in a second set of microspheres.
  • proteins and/ or adjuvants are encapsulated into microspheres via hydrophobic ion pairing (HIP).
  • the invention further provides a method for encapsulating a protein into microspheres wherein HIP is applied to solubilize proteins in an organic medium.
  • the method comprises solubilizing the protein in the presence of a HIP agent and an organic solvent to produce an organic phase comprising the protein.
  • the method further comprises dissolving a polymer in the organic solvent or in the organic phase.
  • Microspheres are then prepared from a polymer solution, wherein the polymer solution comprises the organic phase, the protein, and the polymer.
  • the protein is extracted from an aqueous solution into the organic phase.
  • the solubilizing comprises combining the organic solvent with a dried HIP agent-protein complex.
  • the HIP agent-protein complex can be dried by lyophilization or evaporation, for example.
  • the method enables preparation of microsphere formulations with a single emulsion.
  • the resulting microspheres display desirable release kinetics, i.e., low initial burst and controlled release of the protein over time.
  • the method of encapsulation has been demonstrated to encapsulate proteins of larger sizes than expected, and these encapsulated proteins have demonstrated effective release under physiological conditions. Such encapsulated proteins elicit strong and comprehensive immune responses, including both cellular and humoral immune responses.
  • proteins to be encapsulated in microspheres of the invention include proteins having a molecular weight of at least about 3 kDa, preferably at least about 8 kDa, more preferably at least about 20 kDa. Larger proteins can also be encapsulated into microspheres in accordance with the invention, including those having a molecular weight of at least about 50 kDa, including ICD of her-2/neu, which has a molecular weight of about 66 kDa.
  • Protein antigens to be encapsulated into microspheres of the invention can also be of considerable length, including antigens of at least about 20 amino acid residues in length. Preferably, the protein antigen has a length of at least about 60 amino acid residues, more preferably, at least about 80 amino acids, and most preferably, at least about 100 amino acids in length.
  • the HIP agent is an anionic HIP agent, such as docusate sodium, and the HIP agent is present in stoichiometric amounts equal to or greater than the number of net positive charges on the protein.
  • the HIP agent is a canonic HIP agent, such as dimetl ⁇ yldioctadecyl-ai ⁇ rmoniu ⁇ n bromide (DDAB18); 1,2- dioleoyloxy-3-(trirnethylarnmoniurn)propane (DOTAP); or cetrimonium bromide (CTAB).
  • DDAB18 dimetl ⁇ yldioctadecyl-ai ⁇ rmoniu ⁇ n bromide
  • DOTAP 1,2- dioleoyloxy-3-(trirnethylarnmoniurn)propane
  • CTAB cetrimonium bromide
  • the HIP agent is present in stoichiometric amounts equal to or greater than the number of net negative charges on the protein.
  • the HIP agent and the aqueous solution are selected in accordance with the characteristics of the protein to be encapsulated. Typically, for proteins having an isoelectric point (pi) at or below 7.0, an anionic HIP agent is preferred. Likewise, for proteins having a pi greater than or equal to 7.0, a canonic HIP agent is preferred. For encapsulation of a protein having a pi of about 7.0, either a cationic or anionic HIP agent can be used.
  • the pH of the aqueous solution can be adjusted to achieve the appropriate charge characteristics. Typically, aqueous solutions having low salt concentrations are preferred. In one embodiment, the aqueous solution has a total salt concentration of less than about 30 mM.
  • the method is suitable for proteins having a variety of isoelectric points, including those having a pi of at least about 7.5, at least about 8.0, up to about 6.0, up to about 6.5, as well as pi's of up to or greater than about 7.0.
  • microspheres suitable for use with the method of the invention include, but are not limited to, methylene chloride, dichloromethane, chloroform, efhylacetate, or dimethylsulfoxide.
  • the microspheres can be prepared by a variety of methods known in the art, including a single oil-in-water emulsion, a double oil-in-water emulsion, spray drying or coacervation of the polymer solution.
  • An advantage of the method of the invention is that it allows for preparation of the microspheres by a single emulsion, and thereby obtaining microspheres exhibiting improved release kinetics.
  • at least about 90% of the microspheres are about 1 to about 10 ⁇ in diameter.
  • a preferred polymer for use in the method comprises poly(lactide-co-glycolide) (PLG).
  • PLG poly(lactide-co-glycolide)
  • suitable polymers include poly(lactide), poly(caprolactone), poly(hydroxybutyrate) and/ or copolymers thereof.
  • the polymer solution further comprises an adjuvant, such as MPL, saponin, aluminum phosphate, calcium phosphate, aminoalkylglucosaminide phosphate, isotucerasol, cell wall skeleton, and/ or a CpG- containing oligonucleotide.
  • the protein to be encapsulated in the microspheres typically comprises an antigen, such as an antigen associated with cancer, autoimmune disease or an infectious disease.
  • the infectious disease is tuberculosis.
  • Representative tuberculosis antigens include Mtb8.4, TbH9 (Mtb 39A), 38-1, Mtb41, Mtb40, Mtb32A, Mtb9.9A, Mtb9.8, Mtbl ⁇ , Mtb72f, Mtb59f, Mtb88f, Mtb71f, Mtb46f and Mtb31f.
  • the antigen is associated with breast cancer, such as the intracellular domain (ICD) or extracellular domain (ECD-PD) of her-2/neu.
  • the invention further provides a composition comprising a protein encapsulated in microspheres produced by the method of the invention.
  • the composition preferably further comprises an adjuvant, such as MPL, saponin, AS-2, aluminum phosphate, calcium phosphate, aminoalkylglucosaminide phosphate, isotucerasol, cell wall skeleton, and/ or a CpG-containing oligonucleotide.
  • the adjuvant is co- encapsulated with the antigen in the microspheres.
  • the adjuvant is co-administered with the encapsulated protein antigen.
  • a composition comprising one or more adjuvants encapsulated in microspheres, and methods of delivering adjuvants provided in such a composition.
  • the invention also provides methods for delivering an antigen to a subject, for eliciting an immune response to an antigen in a subject, and for treating or preventing cancer, autoimmune disease or infectious disease in a subject. These methods comprise administering to the subject a composition of the invention.
  • the immune response elicited by the method of the invention includes both a humoral and a cellular immune response.
  • Figure 1 is a graph showing DPV release plotted as a function of time, in days, for five microsphere formulations.
  • the formulations included JA-024, 40% ethyl myristate (C14) (diamonds); AS-011 (squares); AS-012, 15% cholesterol (triangles); AS-014, 20% ethyl caprate (CIO) (X's); AS-013, 20% ethyl stearate (C18) (asterisks); andJA-002, RG-502 (+'s).
  • Figures 2A-C are graphs depicting the results of a CTL assay from an experiment in which mice, in groups of five, were given two 5 ⁇ g immunizations of protein subcutaneously three weeks apart.
  • Mtb8.4 protem-microspheres prepared using the HIP technique of the invention were administered to one group (Fig. 2A); Mtb8.4 protein plus MPL/saponin adjuvant combination was administered to another group (Fig. 2B); and Mtb8.4 protein alone was administered to a third group (Fig. 2C).
  • Closed circles represent lysis of targets transduced with Mtb8.4 DNA. Open circles represents lysis of control EL4 targets.
  • Figures 3A-C are graphs showing that Mtb8.4 protein microspheres prepared using the HIP technique of the invention elicited antibody responses (IgGl; Fig. 3A) that were as strong as those elicited by the MPL/saponin adjuvant combination (Fig. 3B) and significantly stronger than those elicited by protein alone (Fig. 3C). The results from individual mice are shown as individual lines.
  • Figure 5 shows IFN ⁇ release from rMtb8.4 activated spleen cell cultures as determined by intracellular cytokine (ICC) assay.
  • ICC intracellular cytokine
  • FIG. 6 shows IFN ⁇ release from spleen cell cultures as determined by enzyme linked immunosorbant assay (ELISA).
  • Spleen cell cultures (pooled spleens from 3 mice) were activated with recombinant Mtb8.4 for 72 hours.
  • MJ-071b indicates Mtb8.4 encapsulated microspheres without MPL.
  • Figure 7 shows percent specific lysis by CTL response of Mtb8.4-EL4 targets by CD8+ T cells following 5 day activation with irradiated Mtb8.4-EL4 cells.
  • MJ-071b indicates r Mtb8.4 encapsulated microspheres without MPL.
  • Figure 8 shows the percentage of Mtb8.4 cells reactive to CD8+ cells by ICC for IFN ⁇ at 14 days following primary immunization.
  • MJ-073 indicates Mtb8.4 encapsulated microspheres without MPL;
  • MJ-082 indicates microspheres containing both Mtb8.4 and adjuvant (MPL) where MPL was added to the organic phase after protein extraction and before addition to the process media;
  • MJ-083 indicates microspheres containing both Mtb8.4 and adjuvant (MPL) where MPL was incorporated via an inner aqueous phase;
  • MJ-084 indicates microspheres containing both Mtb8.4 and adjuvant (MPL) where MPL was added to the process media in place of the polyvin l alcohol (PVA).
  • PVA polyvin l alcohol
  • Figure 9 shows the percentage of Mtb8.4 cells reactive to CD4+ cells by ICC for IFN ⁇ at 14 days following primary immunization.
  • FIG 10 shows IgGl antibody levels in serum from C57BL/6 mice 14 days following secondary immunization with Mtb8.4-microspheres.
  • FIG 11 shows IgG2b antibody levels in serum from C57BL/6 mice 14 days following secondary immunization with Mtb8.4 microspheres.
  • Figure 12 shows Mtb8.4 dose dependent percent specific lysis by CTL response of Mtb8.4-EL4 targets by CD8+ T cells following 5 day activation with irradiated Mtb8.4- EL4 ceUs.
  • Figure 13 shows Mtb8.4 dose dependent percentage of Mtb8.4 cells reactive to CD4+ cells by ICC for IFN ⁇ at 14 days following primary immunization.
  • Figure 14 shows Mtb8.4 dose dependent percentage of Mtb8.4 cells reactive to CD8+ cells by ICC for IFN ⁇ at 14 days following primary immunization.
  • Figures 15A-D are bar graphs illustrating T-cell responses measured by CD8 (15A and 15C) and CD4 (15B and 15D) ICCS with T-cells harvested two-weeks after a single immunization.
  • Figures 16A-B are bar graphs showing IFN- ⁇ release from spleen cells harvested two- weeks after the primary immunization. Spleens were pooled for this assay.
  • Figures 17A-D are bar graphs showing IgGl and IgG2b serum antibody responses specific for Mtb8.4 in sera obtained two-weeks after the second immunization.
  • Figure 18 is a bar graph showing CTL responses measured two weeks after a single immunization.
  • Figure 19 is a bar graph showing IFN-gamma release from spleen cell cultures measured from mice receiving either a primary immunization or a primary and a secondary immunizations.
  • Figure 20 is a graph illustrating IgG2b serum antibody specific for Mtb8.4 measured two weeks after the mice received a second immunization.
  • Figure 21 is a graph illustrating IgGl serum antibody specific for Mtb8.4 measured two weeks after the mice received a second immunization.
  • the invention disclosed herein is based on the surprising discovery that a strong and comprehensive immune response can be obtained to vaccine compositions comprising protein and adjuvant co-encapsulated in microspheres. Strong immune responses have been obtained using antigens associated with cancer, autoimmune disease and infectious disease. Co-administration of encapsulated protein antigens and separately encapsulated adjuvant elicits a comprehensive immune response, and an even stronger comprehensive immune response can be obtained using protein and adjuvant co-encapsulated in the same set of microspheres. Thus, despite the hydrophobicity of adjuvants tested in the examples provided herein, effective adjuvant delivery has been achieved using adjuvant encapsulated in microspheres. While encapsulation of protein and/ or adjuvant can be achieved by a variety of methods known in the art, the encapsulation is preferably performed via hydrophobic ion pairing as described herein.
  • proteins to be encapsulated in microspheres of the invention include proteins having a molecular weight of at least about 3 kDa, preferably at least about 8 kDa, more preferably at least about 20 kDa. Larger proteins can also be encapsulated into microspheres in accordance with the invention, including those having a molecular weight of at least about 50 kDa, including ICD of her-2/neu, which has a molecular weight of about 66 kDa.
  • Protein antigens to be encapsulated into microspheres of the invention can also be of considerable length, including antigens of at least about 20 amino acid residues in length.
  • the protein antigen has a length of at least about 60 amino acid residues, more preferably, at least about 80 amino acids, and most preferably, at least about 100 amino acids in length.
  • Hydrophobic ion pairing involves stoichiometric replacement of polar counter ions with a species of similar charge but less easily solvated.
  • the invention provides a method that uses HIP to change the solubility properties of proteins, allowing extraction of the protein into an organic solvent, such as methylene chloride.
  • Docusate sodium (Bis(2-eth.ylhexyl) sodium sulfosuccinate) is one example of a suitable ion-pairing agent.
  • methylene chloride containing docusate sodium is mixed with an aqueous protein solution. This results in ion-pairing of the docusate ion with the protein and subsequent partitioning of the protein into the oil phase. Dissolution of the protein in methylene chloride allows the protein to be encapsulated in microspheres prepared via a single oil-in-water emulsion method.
  • Microspheres prepared by this method exhibit desirable protein release characteristics, including low initial burst release and a gradual release of protein over time.
  • the release kinetics may be further modified by incorporating additives such as cholesterol and esters of fatty acids, which are soluble in the organic solvent.
  • the invention provides microsphere formulations encapsulating a protein antigen, wherein the protein antigen is released gradually over time.
  • Use of HIP to produce microspheres in accordance with the invention allows for a more even distribution of the protein within the microspheres, and reduces aggregation of the protein in the microspheres.
  • protein or “polypeptide” means a polymer of at least about 20 or, more typically, at least about 50 amino acids. Such proteins or polypeptides have primary, secondary, tertiary and, in some cases, quaternary, structures.
  • the protein or polypeptide can be isolated from natural sources, produced by recombinant techniques or chemically synthesized.
  • immune response includes the production of antibodies, production of immunomodulators such as IFN- ⁇ , and induction of CTL activity.
  • the elicitation of an immune response includes the initiation, stimulation or enhancement of an immune response.
  • a “comprehensive immune response” refers to a response that includes both humoral and cellular immune responses.
  • to "prevent” or “protect against” a condition or disease means to hinder, reduce or delay the onset or progression of the condition or disease.
  • antigen-presenting cell means a cell capable of handling and presenting antigen to a lymphocyte.
  • APCs include, but are not limited to, macrophages, Langerhans-dendritic cells, follicular dendritic cells, B cells, monocytes, fibroblasts and fibrocytes.
  • Dendritic cells are a preferred type of antigen presenting cell. Dendritic cells are found in many non-lymphoid tissues but can migrate via the afferent lymph or the blood stream to the T-dependent areas of lymphoid organs. In non- lymphoid organs, dendritic cells include Langerhans cells and interstitial dendritic cells. In the lymph and blood, they include afferent lymph veiled cells and blood dendritic cells, respectively. In lymphoid organs, they include lymphoid dendritic cells and interdigitating cells.
  • modified to present an epitope refers to antigen-presenting cells (APCs) that have been manipulated to present an epitope by natural or recombinant methods.
  • APCs antigen-presenting cells
  • the APCs can be modified by exposure to the isolated antigen, alone or as part of a mixture, peptide loading, or by genetically modifying the APC to express a polypeptide that includes one or more epitopes.
  • salts refers to a salt that retains the desired biological activity of the parent compound and does not impart any undesired toxicological effects.
  • examples of such salts include, but are not limited to, (a) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; and salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, furmaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphfhalenesulfonic acids, naphthalenedisulfonic acids, polygalacturonic acid; (b) salts with polyvalent metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobal
  • pharmaceutically acceptable carrier includes any material which, when combined with an active ingredient, allows the ingredient to retain biological activity and is non-reactive with the subject's immune system.
  • examples include, but are not limited to, any of the standard pharmaceutical carriers such as a phosphate buffered saline solution, water, emulsions such as oil/ ater emulsion, and various types of wetting agents.
  • Preferred diluents for aerosol or parenteral administration are phosphate buffered saline or normal (0.9%) saline.
  • compositions comprising such carriers are formulated by well known conventional methods (see, for example, Remington's Pharmaceutical Sciences, 18th edition, A. Gennaro, ed., Mack Publishing Co., Easton, PA, 1990).
  • adjuvant includes those adjuvants commonly used in the art to facilitate the stimulation of an immune response.
  • encapsulation of protein and/ or adjuvant can be achieved by a variety of methods known in the art, the encapsulation is preferably performed via hydrophobic ion pairing as described herein.
  • Other microsphere encapsulation methods are described in WO02/03961 (PCT/US01/21780, filed July 9, 2001) and PCT/US02/00235, filed January 7, 2002.
  • the invention provides a method for encapsulating a protein and/ or adjuvant into microspheres via hydrophobic ion pairing (HIP).
  • the method comprises extracting an aqueous solution comprising the protein with an organic solvent containing a HIP agent to produce an extraction product having an organic phase comprising the protein.
  • the method further comprises recovering the organic phase from the extraction product, and dissolving a polymer in the aqueous solution or in the organic phase.
  • Microspheres are then prepared from a polymer solution, wherein the polymer solution comprises the recovered organic phase, the protein, and the polymer.
  • Hydrophobic ion pairing allows extraction of protein into an organic medium, thereby allowing microsphere formulations to be prepared with a single emulsion.
  • the resulting microspheres display desirable release kinetics, i.e., low initial burst and controlled release of the protein over time.
  • the HIP agent is an anionic HIP agent, such as docusate sodium, and the HIP agent is present in stoichiometric amounts equal to or greater than the number of net positive charges on the protein.
  • the HIP agent is a canonic HIP agent, such as dimethyldioctadecyl-ammonium bromide (DDAB18); 1,2- cnoleoyloxy-3-(trimethylammonium)propane (DOTAP); or cetrimonium bromide
  • the HIP agent is present in stoichiometric amounts equal to or greater than the number of net negative charges on the protein.
  • the organic medium has a ratio of HIP agent to protein of up to about 70:1.
  • the HIP agent and the aqueous solution are selected in accordance with the characteristics of the protein to be encapsulated. Typically, for proteins having an isoelectric point (pi) at or below 7.-0, an anionic HIP agent is preferred. Likewise, for proteins having a pi greater than or equal to 7.0, a canonic HIP agent is preferred. For encapsulation of a protein having a pi of about 7.0, either a canonic or anionic HIP agent can be used.
  • the pH of the aqueous solution can be adjusted to achieve the appropriate charge characteristics. Typically, aqueous solutions having low salt concentrations are preferred. In one embodiment, the aqueous solution has a total salt concentration of less than about 30 mM.
  • the method is suitable for proteins having a variety of isoelectric points, including those having a pi of at least about 7.5, at least about 8.0, up to about 6.0, up to about 6.5, as well as pi's of up to or greater than about 7.0.
  • a protein solution containing low concentrations of calcium cliloride and other salts (preferably less than 30 mM total) is adjusted to a pH of 3 to 5 (preferably at least two pH units below the pi of the protein).
  • the aqueous protein solution is then extracted with an organic medium containing an HIP agent, such as docusate sodium.
  • the docusate sodium is present in stoichiometric amounts equal to or greater than the number of positive charges on the protein.
  • the organic phase can be recovered from the extraction by centrifugation.
  • a polymer and additives that are soluble in an organic solvent, such as methylene chloride, are then dissolved in the organic phase with the protein.
  • the polymer could also be added to the protein solution prior to the extraction.
  • the salt concentrations in the protein solution and the concentration of the HIP agent can be varied to obtain cleaner separation of the two phases upon centrifugation.
  • the pH can be optimized for a given protein.
  • organic solvents suitable for use with the method of the invention include, but are not limited to, methylene chloride, dichloromethane, chloroform, efhylacetate, or dimefhylsulfoxide. Methylene chloride is preferred.
  • the microspheres can be prepared by a variety of methods known in the art, including a single oil-in-water emulsion, a double oil-in-water emulsion, spray drying or coacervation of the polymer solution.
  • An advantage of the method of the invention is that it allows for preparation of the microspheres by a single emulsion, and thereby obtaining microspheres exhibiting improved release kinetics.
  • the method of the invention will result in the formation of microspheres of a suitable size for administration and delivery of proteins, particularly as vaccines.
  • a suitable size for administration and delivery of proteins particularly as vaccines.
  • at least about 90% of the microspheres are about 1 to about 10 ⁇ m in diameter.
  • microspheres of the invention preferably comprise a biodegradable polymer, such as poly(lacto-co-glycolide) (PLG), poly( ctide), poly(caprolactone), poly(hydroxybutyrate) and/ or copolymers thereof.
  • PLA poly(lacto-co-glycolide)
  • poly( ctide) poly(caprolactone)
  • poly(hydroxybutyrate) poly(hydroxybutyrate)
  • copolymers thereof e.g., poly(lacto-co-glycolide) (PLG), poly( ctide), poly(caprolactone), poly(hydroxybutyrate) and/ or copolymers thereof.
  • PLG poly(lacto-co-glycolide)
  • caprolactone poly(hydroxybutyrate)
  • copolymers thereof e.glymer of poly(hydroxybutyrate)
  • the microspheres can comprise another wall- forming material.
  • Suitable waU-forming materials include, but are not limited to, poly(dienes) such as poly(butadiene) and the like; poly(alkenes) such as polyethylene, polypropylene, and the like; poly(acrylics) such as poly(acrylic acid) and the like; poly(methacrylics) such as poly(mefhyl methacrylate), poly(hydroxyethyl methacrylate), and the like; poly(vinyl ethers); poly(vinyl alcohols); poly(vinyl ketones); poly(vinyl halides) such as poly(vinyl chloride) and the like;, poly(vinyl nitriles), poly(vinyl esters) such as poly(vinyl acetate) and the like; poly(vinyl pyridines) such as poly(2-vinyl pyridine), poly(5-methyl-2-vinyl pyridine) and the like; polystyrenes); polycarbonates); poly(esters); poly(ortho
  • Biodegradable microspheres e.g., polylactate polyglycolate
  • Biodegradable microspheres for use as carriers are disclosed, for example, in U.S. Patent Nos. 4,897,268; 5,075,109; 5,928,647; 5,811,128; 5,820,883; 5,853,763; 5,814,344; 5,407,609; and 5,942,252; the disclosures of each of which are incorporated herein by reference.
  • the polymer comprises PLG.
  • the PLG can include ester end groups or carboxylic acid end groups, and have a molecular weight of from about 4 kDa to about 120 kDa, or preferably, about 8 kDa to about 65 kDa.
  • the polymer solution further comprises an adjuvant.
  • adjuvants include, but are not limited to, helper peptide; aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (Smith-Kline Beecham); QS-21 (Aquilla); MPLTM i munostimulant or 3d-MPL (Corixa Corporation); LEIF; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A; muramyl tripeptide phosphatidyl ethanolarnine or an irnmunostimulating complex, including cytokines
  • Preferred adjuvants include MPL, saponin, aluminum phosphate, calcium phosphate, aminoalkylglucosaminide phosphate, isotucerasol, cell wall skeleton, and/or a CpG-containing oligonucleotide.
  • the release rate of the microspheres will be influenced by the properties of the buffer used. For example, HEPES buffer will result in slower release than Tris buffer.
  • HEPES buffer will result in slower release than Tris buffer.
  • fatty acid esters and cholesterol into microspheres to modify the release kinetics of encapsulated drug has been described by Urata et al., 1999, J. Controlled Release 58:133-141, and these principles can be adapted for use with encapsulated proteins.
  • fatty acid esters include, but are not limited to, ethyl myristate (C14), ethyl caprate (CIO) and ethyl stearate (C18).
  • the protein to be encapsulated in the microspheres typically comprises an antigen, such as an antigen associated with cancer, autoimmune disease or an infectious disease.
  • cancer include, but are not limited to, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronch
  • her2/neu a breast cancer antigen
  • breast cancer antigen a cancer antigen
  • her-2/neu antigens include, but are not limited to, the intracellular domain of her-2/neu (ICD, amino acid residues 676-1255; see Bargmann et al.
  • p369 also known as E75; KLFGSLAFL; SEQ ID NO: 1 of the extracellular domain of her-2/neu, ECD- PD (fusion of extracellular domain and phosphorylated portion of the intracellular domain; see WO02/12341, published February 14, 2002, and WO00/44899, published August 3, 2000), and p546, a transmembrane region of her-2/neu (VLQGLPREYV; SEQ ID NO: 2).
  • infectious disease include, but are not limited to, infection with a pathogen, virus, bacterium, fungus or parasite.
  • viruses include, but are not limited to, hepatitis type B or type C, influenza, varicella, adenovirus, herpes simplex virus type I or type II, rinderpest, rhinovitus, echovirus, rotavirus, respiratory syncytial virus, papilloma virus, papova virus, cytomegalovirus, echinovirus, arbovitus, hantavirus, coxsachie virus, mumps virus, measles virus, rubella virus, polio virus, human immunodeficiency virus type I or type II.
  • bacteria include, but are not limited to, M. tuberculosis, mycobacterium, mycoplasma, neisseria and legionella.
  • parasites include, but are not limited to, rickettsia and chlamydia.
  • the infectious disease is tuberculosis.
  • Representative tuberculosis antigens include Mtb8.4, TbH9 (Mtb 39A), 38-1, Mtb41, Mtb40, M ⁇ 32A, Mtb9.9A, Mtb9.8, Mtbl ⁇ , Mtb72f, Mtb59f, Mtb88f, Mtb71f, Mtb46f and Mtb31f.
  • the "f ' indicates a fusion or two or more proteins.
  • the invention provides compositions that are useful for delivering proteins and/ or adjuvants.
  • the proteins encapsulated in microspheres can include antigens associated with cancer, autoimmune disease or infectious disease, providing compositions for treating and preventing cancer or infectious disease.
  • the composition is a pharmaceutical composition.
  • the composition can comprise a therapeutically or prophylacticaUy effective amount of a protein that includes one or more antigens associated with cancer, autoimmune disease, or infectious disease.
  • An effective amount is an amount sufficient to elicit or augment an immune response, e.g., by activating T cells.
  • One measure of the activation of T cells is a cytotoxicity assay or an interferon-gamma release assay, as described in the examples below.
  • the composition is a vaccine.
  • compositions of the present invention can optionally include a carrier, such as a pharmaceutically acceptable carrier.
  • a carrier such as a pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions of the present invention.
  • Formulations suitable for parenteral administration such as, for example, by intraarticular (in the joints), intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous routes, and carriers include aqueous isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, preservatives and emulsions.
  • aqueous isotonic sterile injection solutions which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient
  • aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, preservatives and emulsions.
  • composition of the invention can further, or alternatively, comprise one or more adjuvants.
  • Adjuvant can be encapsulated in microspheres, together with or separately from protein. Alternatively, or in addition, adjuvant can be provided in the composition using a conventional formulation rather than encapsulation in microspheres.
  • adjuvants include, but are not limited to, helper peptide, alum, Freund's, muramyl tripeptide phosphatidyl ethanolamine or an iminunostirnulating complex, including cytokines.
  • Preferred adjuvants include MPL, saponin, AS-2, aluminum phosphate, calcium phosphate, ammoalkylglucosaminide phosphate, isotucerasol, cell wall skeleton, and/ or a CpG-containing oligonucleotide.
  • adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, ortadell pertussis or Mycobacterium tuberculosis derived proteins.
  • Suitable adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM CSF or interleukin-2, -7, or -12, may also be used as adjuvants.
  • the adjuvant composition is preferably designed to induce an immune response predominantly of the Thl type.
  • High levels of Thl-type cytokines e.g., IFN- ⁇ , IL-2 and LL-12
  • Th2-type cytokines e.g., LL-4, IL-5, IL-6, IL-10 and TNF- ⁇
  • a patient will support an immune response that includes Thl- and Th2-type responses.
  • Thl-type cytokines will increase to a greater extent than the level of Th2-type cytokines.
  • the levels of these cytokines may be readily assessed using standard assays. For a review of the families of cytokines, see Mosmann and Coffman, 1989, Ann. Rev. Immunol. 7:145-173.
  • Preferred adjuvants for use in eliciting a predominantly Thl-type response include, for example, a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A (3D-MPL), together with an aluminum salt.
  • MPL adjuvants are available from Corixa Corporation (Hamilton, MT) (see US Patent Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094).
  • CpG-containing oligonucleotides in which the CpG dinucleotide is unmethylated also induce a predominantly Thl response. Such oligonucleotides are well known and are described, for example, in WO 96/02555.
  • Another preferred adjuvant is a saponin, preferably QS21, which may be used alone or in combination with other adjuvants.
  • an enhanced system involves the combination of a monophosphoryl lipid A and saponin derivative, such as the combination of QS21 and 3D-MPL as described in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol, as described in WO 96/33739.
  • Other preferred formulations comprises an oil-in-water emulsion and tocopherol.
  • a particularly potent adjuvant formulation involving QS21, 3D-MPL and tocopherol in an oil-in-water emulsion is described in WO 95/17210.
  • compositions and vaccines within the scope of the present invention may also contain other compounds, which may be biologically active or inactive.
  • compositions may also comprise buffers (e.g., neutral buffered saline or phosphate buffered saline), carbohydrates (e.g., glucose, mannose, sucrose or dextrans), mannitol, proteins, polypeptides or a ino acids such as glycine, antioxidants, chelating agents such as EDTA or gluta hione, adjuvants (e.g., aluminum hydroxide) and/or preservatives.
  • buffers e.g., neutral buffered saline or phosphate buffered saline
  • carbohydrates e.g., glucose, mannose, sucrose or dextrans
  • mannitol e.g., proteins, polypeptides or a ino acids such as glycine
  • antioxidants e.g., chelating agents such as EDTA or gluta hione
  • adjuvants e.g., aluminum hydroxide
  • preservatives e.g., aluminum hydroxide
  • compositions described herein may be atdministered as part of a sustained release formulation (i.e., a formulation such as a capsule or sponge that effects a slow release of compound following aciministration).
  • a sustained release formulation i.e., a formulation such as a capsule or sponge that effects a slow release of compound following aciministration.
  • Such formulations may generally be prepared using well known technology and administered by, for example, oral, rectal or subcutaneous implantation, or by implantation at the desired target site.
  • Sustained-release formulations may contain a polypeptide or protein dispersed in a carrier matrix and/ or contained within a reservoir surrounded by a rate controlling membrane.
  • Carriers for use within such formulations are biocompatible, and may also be biodegradable; preferably the formulation provides a relatively constant level of active component release.
  • the amount of active compound contained within a sustained release formulation depends upon the site of implantation, the rate and expected duration of release and the nature of the condition to be treated or prevented.
  • the invention also provides methods for delivering a protein or an adjuvant to a subject , for eliciting an immune response to an antigen in a subject, and for treating or preventing a condition in a subject. These methods comprise administering to the subject a composition of the invention. Administration may be performed as described below.
  • the condition to be treated or prevented is cancer or a precancerous condition (e.g., hyperplasia, metaplasia, dysplasia). Examples of cancer are listed hereinabove.
  • the condition to be treated or prevented is an autoimmune disease or infectious disease.
  • infectious disease include the viral, bacterial and parasitic diseases described hereinabove.
  • an infectious disease is tuberculosis.
  • autoimmune disease include allergy, insulin-dependent diabetes mellitus, systemic lupus erythematosus, pernicious anemia, Hashimoto's thyroiditis, Addison's disease, dermatomyositis, and rheumatoid arthritis.
  • Treatment includes prophylaxis and therapy.
  • Prophylaxis or treatment can be accomplished by a single direct injection at a single time point or multiple time points. A ⁇ lministration can also be nearly simultaneous to multiple sites.
  • Patients or subjects include mammals, such as human, bovine, equine, canine, feline, porcine, and ovine animals. Preferably, the patients or subjects are human.
  • compositions are typically administered in vivo via parenteral (e.g. intravenous, subcutaneous, and intramuscular) or other traditional direct routes, such as buccal/sublingual, rectal, oral, nasal, topical, (such as transdermal and ophthalmic), vaginal, pulmonary, intraarterial, intraperitoneal, intraocular, or intranasal routes or directly into a specific tissue. Intramuscular administration is preferred.
  • parenteral e.g. intravenous, subcutaneous, and intramuscular
  • other traditional direct routes such as buccal/sublingual, rectal, oral, nasal, topical, (such as transdermal and ophthalmic), vaginal, pulmonary, intraarterial, intraperitoneal, intraocular, or intranasal routes or directly into a specific tissue.
  • parenteral e.g. intravenous, subcutaneous, and intramuscular
  • other traditional direct routes such as buccal/sublingual, rectal, oral, nasal, topical, (such as transdermal
  • the dose administered to a patient should be sufficient to effect a beneficial therapeutic response in the patient over time, or to inhibit infection or disease due to infection.
  • the composition is administered to a patient in an amount sufficient to elicit an effective immune response to the specific antigens and/or to alleviate, reduce, cure or at least partially arrest or prevent symptoms and/or complications from the disease or infection.
  • An amount adequate to accomplish this is defined as a "therapeutically effective dose.”
  • the dose will be determined by the activity of the composition produced and the condition of the patient, as well as the body weight or surface areas of the patient to be treated.
  • the size of the dose also will be determined by the existence, nature, and extent of any adverse side effects that accompany the ac riinistration of a particular composition in a particular patient.
  • the physician needs to evaluate the production of an immune response against the pathogen, progression of the disease, and any treatment-related toxicity.
  • compositions comprising immune cells are preferably prepared from immune cells obtained from the subject to whom the composition will be administered.
  • the immune cells can be prepared from an HLA-compatible donor.
  • the immune cells are obtained from the subject or donor using conventional techniques known in the art, exposed to APCs modified to present an epitope of the invention, expanded ex vivo, and administered to the subject. Protocols for ex vivo therapy are described in Rosenberg et al., 1990, New England J. Med. 9:570-578.
  • Immune cells may generally be obtained in sufficient quantities for adoptive immuno herapy by growth in vitro, as described herein.
  • Culture conditions for expanding single antigen-specific effector cells to several billion in number with retention of antigen recognition in vivo are well known in the art.
  • Such in vitro culture conditions typically use intermittent stimulation with antigen, often in the presence of cytokines (such as IL-2) and non-dividing feeder cells.
  • cytokines such as IL-2
  • immunoreactive polypeptides as provided herein may be used to enrich and rapidly expand antigen-specific T cell cultures in order to generate a sufficient number of cells for immunofherapy.
  • antigen-presenting cells such as dendritic, macrophage, monocyte, fibroblast and/ or B cells
  • antigen-presenting cells may be pulsed with immunoreactive polypeptides using standard techniques well known in the art.
  • antigen-presenting cells can be transfected with a polynucleotide having a promoter appropriate for increasing expression in a recombinant virus or other expression system.
  • Cultured effector cells for use in therapy must be able to grow and distribute widely, and to survive long term in vivo.
  • Administration by many of the routes of administration described herein or otherwise known in the art may be accomplished simply by direct administration using a needle, catheter or related device, at a single time point or at multiple time points.
  • a composition of the invention may be employed to facilitate production of an antigen- specific immune response that targets cancerous or infected cells.
  • Certain preferred embodiments of the present invention use dendritic cells or progenitors thereof as antigen-presenting cells (APCs).
  • APCs antigen-presenting cells
  • Dendritic cells are highly potent APCs (Banchereau and Steinman, Nature 392:245-251, 1998) and have been shown to be effective as a physiological adjuvant for eliciting prophylactic or therapeutic immunity (see Tirnmerrnan and Levy, Ann. Rev. Med. 50:507-529, 1999).
  • dendritic cells may be identified based on their typical shape (stellate in situ, with marked cytoplasmic processes (dendrites) visible in vitro) and based on the lack of differentiation markers of B cells (CD19 and CD20), T cells (CD3), monocytes (CD14) and natural killer cells (CD56), as determined using standard assays.
  • Dendritic cells may, of course, be engineered to express specific cell-surface receptors or ligands that are not commonly found on dendritic cells in vivo or ex vivo, and such modified dendritic cells are contemplated by the present invention.
  • dendritic cells secreted vesicles antigen-loaded dendritic cells (called exosomes) may be used within a vaccine (Zitvogel et al., 1998, Nature Med. 4:594-600).
  • Dendritic cells and progenitors may be obtained from peripheral blood, bone marrow, ttLmor-mfnttating cells, peritumoral tissues-infiltrating cells, lymph nodes, spleen, skin, umbilical cord blood or any other suitable tissue or fluid.
  • dendritic cells may be differentiated ex vivo by adding a combination of cytokines such as GM-CSF, IL- 4, IL-13 and/ or TNF to cultures of monocytes harvested from peripheral blood.
  • CD34 positive cells harvested from peripheral blood, umbilical cord blood or bone marrow may be differentiated into dendritic cells by adding to the culture medium combinations of GM-CSF, LL-3, TNF ⁇ , CD40 ligand, LPS, flt3 ligand and/or other compound(s) that induce maturation and proliferation of dendritic cells.
  • Dendritic cells are conveniently categorized as “immature” and “mature” cells, which allows a simple way to cuscriminate between two well characterized phenotypes. However, this nomenclature should not be construed to exclude all possible intermediate stages of differentiation. Immature dendritic cells are characterized as APC with a high capacity for antigen uptake and processing, which correlates with the high expression of Fc ⁇ receptor, mannose receptor and DEC-205 marker.
  • the mature phenotype is typically characterized by a lower expression of these markers, but a high expression of cell surface molecules responsible for T cell activation such as class I and class II MHC, adhesion molecules (e.g., CD54 and CD11) and costimulatory molecules (e.g., CD40, CD80 and CD86).
  • APCs may be combined with a protein encapsulated in a microsphere of the invention such that the APCs can take up and express the polypeptide, or an immunogenic portion thereof, which is expressed on the cell surface.
  • Antigen loading of dendritic cells may be achieved by incubating dendritic cells or progenitor cells with the encapsulated protein.
  • a dendritic cell may be pulsed with an immunological partner that provides T cell help (e.g., a carrier molecule).
  • Example 1 Protem-Microsphere Formulations
  • This example describes the preparation of prote -microsphere and protein-adjuvant- microsphere formulations.
  • microsphere formulations were prepared, m the absence of adjuvant, usmg a hydrophobic ion pair (HIP) technique.
  • 3 mg of lyophikzed protem was dissolved m 2.7 ml of ultra-pure water.
  • To this protem solunon was added 0.3 ml of a 100 mM CaCl 2 solution and 55 ⁇ l of 0.1 M HCl, to lower the pH into the pH 3-5 range.
  • the protem was extracted into the organic phase, 4.3 mM AOT (docusate sodium) m dichloromethane, by vortex mixing.
  • the orgamc phase containmg the protem, was separated from the aqueous phase by centrifugation.
  • the aqueous phase was discarded and the volume of orgamc was brought up to 10 ml through the addition of DCM.
  • PLG polymer 300 mg of RG502H; Boehrmger Ingelheim GmbH (Ingelheim, Germany) was then dissolved in the solvent. Formation of the microspheres was achieved through the addition of the protem and polymer m orgamc phase to 400 ml of a 5% PVA (polyvinyl alcohol) aqueous solution with a Silverson mixer at 9000 rpm for approximately 1 minute. The microspheres were stirred gently for 2-3 hours to allow hardening and then washed and collected by centrifugation. Manntitol was added prior to freezmg and lyophiUzation as an excipient.
  • PVA polyvinyl alcohol
  • microspheres contained both protem (Mtb8.4; also referred herein as DPV) and adjuvant (MPL).
  • Mtb8.4 also referred herein as DPV
  • MPL adjuvant
  • microspheres contained both protein (Mtb8.4) and adjuvant (MPL). As they were co-encapsulated, the ratio of protein to MPL was fixed and was ⁇ 1:1.
  • This formulation was prepared in the same general manner as MJ071b/MJ087b, with the exception of the MPL addition.
  • the MPL (3 mg) was incorporated via an inner aqueous phase. That is, 3 mg of MPL was first dispersed in 1.0 ml of water with aggressive vortex mixing. After addition of PLG polymer to the DCM containing protein phase, this 1.0 ml of MPL in water phase was added and emulsified by vortex mixing for 30 seconds. This primary emulsion was then emulsified in 400 ml of 5% PVA as before.
  • microspheres contained both protein (Mtb8.4) and adjuvant (MPL).
  • Mtb8.4 protein
  • MPL adjuvant
  • the ratio of protein to MPL was fixed and was 0.37.
  • This formulation was prepared in the same manner as MJ071b/MJ087b with the sole exception that 3 mg of MPL was added to the 400 ml of process media in place of the PVA, the emulsion was mixed at 9000 rpm for 2- 1/2 minutes after which the dispersion was further diluted by adding an additional 300 ml of ultra-pure water.
  • the example shows the in vitro release of DPV protein into a release medium composed of 150 mM Tris, pH 8.1, and 0.01% Tween 20.
  • DPV is a 9 kilodalton protein with a pi of 6.5.
  • Figure 1 shows DPV release plotted as a function of time for five microsphere formulations.
  • the formulations included JA-024, 40% ethyl myristate (C14) (diamonds); AS-011 (squares); AS-012, 15% cholesterol (triangles); AS-014, 20%o ethyl caprate (CIO) (X's); AS-013, 20% ethyl stearate (C18) (asterisks); andJA-002, RG-502 (+'s).
  • the formulations were each prepared by a single emulsion method in which the DPV protein was solubilized in methylene chloride via hydrophobic ion pairing (HIP) with docusate sodium.
  • Formulation AS-011 through AS-014 were prepared using PLG RG-592H polymer.
  • Cholesterol and fatty acid esters were included in some embodiments, as noted above.
  • FIG. 2A Mice that were immunized with microencapsulated protein (Fig. 2A) elicited the strongest, most consistent immune responses, compared with the responses elicited by protein plus MPL/saponin (Fig. 2B) and protein alone (Fig. 2C). Mice were immunized on DO and D21 with 5 ⁇ g of protein subcutaneously. Spleens were harvested on D35.
  • FIG. 3A This example describes an experiment in which antibody responses (IgGl) were measured from sera obtained on the day of harvest.
  • the protein microspheres prepared using the HIP technique of the invention elicited a strong antibody response in all five mice studied (Fig. 3A). These responses were significantiy stronger than those elicited by protein alone (Fig. 3B) and equivalent to those elicited by the MPL/saponin adjuvant combination (Fig. 3C).
  • Mice, in groups of five, were immunized on DO and D21 with 5 ⁇ g of protein subcutaneously. Sera were collected on D35 and specific antibody levels were measured by ELISA. The results from individual mice are shown.
  • Example 5 HIP Microspheres Elicit Stronger and More Consistent Immune Responses in Mice Than Immunization With DNA or Protein /Adjuvant Combination
  • FIG. 4 shows the results from a mouse experiment that compared the ability of a Mtb8.4 protein-microsphere to elicit CTL responses with those elicited by DNA immunizations and protein plus the MPL/saponin adjuvant combination.
  • Closed symbols represent lysis of targets transduced with Mtb8.4 DNA. Open symbols represents lysis of control EL4 targets.
  • strong CTL response was measured for the group receiving protem-microspheres (circles). This response was significantly stronger than the response measured for the protein plus MPL/saponin group (triangles) and, remarkably, comparable to the response for the group that received DNA (squares).
  • FIGS 5-7 show ICC, ELISA and CTL data, respectively, for C57BL/6 mice immunized one or two times with 12 ⁇ g of Mtb8.4-microspheres or protein + adjuvant.
  • Vaccines were given via subcutaneous administration with 21 days between the primary and secondary immunizations.
  • Mtb8.4-DNA immunizations mice were administered 50 ⁇ g of plasmid DNA via intramuscular injection. Mice were harvested at various times post secondary immunizations and analyzed for anti-Mfb8.4 immune responses.
  • CTL Assay Specific lysis of Mtb8.4-EL4 targets by CD8+ T-cells.
  • ICC Assay Intracellular cytokine staining of CD8+ and CD4+ T-cells following a 5 hr activation with Mtb8.4 peptides.
  • IFN ⁇ ELISA IFN ⁇ release from rMtb8.4 activated spleen cell cultures.
  • FIG. 5 shows that C57B1/6 mice were administered a single subcutaneous (SC) or intradermal (ID) immunization with recombinant Mtb8.4 protein plus PBS, Mfb8.4 encapsulated in microspheres (MJ-071b), Mtb8.4 protein plus adjuvant (RC-529-AF), or Mtb8.4 surface adsorbed microspheres (AM-008).
  • SC subcutaneous
  • ID intradermal
  • FIG. 6 shows that C57B1/6 mice were administered one or two subcutaneous (SC) immunizations with recombinant Mtb8.4 protein plus PBS, Mtb8.4 encapsulated in microspheres (MJ-071b), Mt8.4 protein + adjuvant (MPL-AF, 557-AF, 544-AF), or Mtb8.4 DNA (intramuscular immunization).
  • SC subcutaneous
  • FIG. 7 shows that C57B1/6 mice were administered a single subcutaneous (SC) immunization with recombinant Mtb8.4 protein plus PBS, Mtb8.4 encapsulated in microspheres (MJ-071b), Mtb8.4 protein plus adjuvant (MPL-AF, 557-AF, 544-AF), or Mtb8.4 (intramuscular immunization).
  • SC subcutaneous
  • Mtb8.4 protein plus PBS Mtb8.4 encapsulated in microspheres
  • MPL-AF Mtb8.4 protein plus adjuvant
  • 557-AF 544-AF
  • Mtb8.4 intramuscular immunization
  • Example 6 Co-encapsulated Mtb8.4 Protein and Adjuvant (MPL) in Microspheres Induces a S nergistic Response Enhancing Thl and B-cell Mediated Immunity against Mtb8.4.
  • MPL Protein and Adjuvant
  • Figures 8 and 9 show the enhancement in CD8 and CD4 T-cell immune responses, respectively, against Mtb8.4 following a single immunization with MPL co-encapsulated microspheres.
  • C57B1/6 mice were immunized (ID) with Mtb8.4-microspb.eres (MJ-073) or MPL co-encapsulated Mtb8.4-microspheres prepared using three different methods
  • Figures 10 and 11 show the enhancement in IgGi and IgG 2 b antibody responses, respectively, against Mtb8.4 following a single immunization with MPL co-encapsulated microspheres.
  • Serum was collected from C57B1/6 mice 14 days following the secondary immunization with Mtb8.4-microspheres (MJ-073), MPL co-encapsulated Mtb8.4- microspheres (MJ082, MJ083, MJ084) or Mtb8.4 surface adsorbed microspheres (MJ085) and evaluated for anti-Mtb8.4 IgGi and IgG 2 b antibodies ( Figures 10 and 11, respectively) by ELISA.
  • Example 7 Dose Response of Mtb8.4 and MPL Co-Encapsulated Microspheres.
  • This example discloses the dose response of the MJ-082 protein-MPL co-encapsulation in inducing specific CTL-mediated lysis of Mtb8.4-EL4 target cells, CD4+ T-cell IFN ⁇ release, and CD8+ T-cell IFN ⁇ release. ( Figures 12, 13 and 14; respectively).
  • CTL and ICC assays were performed as described elsewhere herein and further support the synergistic effect on CD4 and CD8 T-cell immune responses when an adjuvant, such as monophosphoryl lipid A (MPL®), is co-encapsulated in the Mtb8.4-microspb.eres.
  • MPL® monophosphoryl lipid A
  • This example demonstrates several aspects of optimal vaccine formulations in accordance with the invention.
  • coencapsulation of protein (Mtb8.4) and another adjuvant (RC529) is effective at eliciting CD8+ and CD4+ T-cell responses, CTL, IFN- gamma, and antibody (IgGl and IgG2a) immune responses.
  • the comprehensive immune response to coencapsulated protein and adjuvant is not limited to a single adjuvant.
  • encapsulating protein and adjuvant separately and admixing does elicit comprehensive immune responses.
  • having the antigen and the adjuvant encapsulated in the same particles however, elicits stronger responses than encapsulating in separate particles and admixing.
  • adjuvant (MPL or 529) encapsulated in microspheres is at least as effective as adjuvant formulated in the standard aqueous formulation (i.e., liposomes).
  • This novel means of delivering adjuvant, via encapsulation in microspheres, provides an attractive alternative to conventional adjuvant delivery.
  • Mtb8.4 was used as the protein antigen.
  • RC529 a synthetic ammoalkylglucosaminide phosphate, was used to address the first point, while MPL and 529 were both used to address the subsequent points.
  • Microspheres were prepared containing (a) Mtb8.4 protein alone, (b) MPL® adjuvant alone, (c) RC529 adjuvant alone, (d) Mtb8.4 protein and MPL co-encapsulated, and (e) Mtb8.4 protein and 529 co-encapsulated. Essentially the same method was used to prepare all five types of microspheres with the only difference being in the components that were added.
  • Microsphere Preparation The same method of microsphere preparation was utilized to prepare the various formulations for this example with the only difference being the components (+/- Mtb8.4 protein, +/-MPL® adjuvant, +/- RC529 adjuvant) that were added. This is the same method that was described in Examples 1, 6, and 7 above. In brief, an aqueous acidic solution was extracted using a dichloromethane solution of docusate sodium. For formulations having protein, the Mtb8.4 protein (3 mg) was in the acid aqueous solution and extracted into the organic phase. Adjuvant (MPL or 529) was then added to the organic phase as required, followed by 300 mg of PLG (RG502H).
  • Adjuvant MPL or 529
  • the organic phase was then emulsified into 400 ml of 5% PVA using a Silverson homogenizer.
  • the solvent was extracted by stirring in a fume-hood for several hours.
  • the microspheres were then washed several times and lyophilized. Mannitol was added prior to lyophilization.
  • Microsphere Characterization The protein and adjuvant contents of the microspheres were determined by HPLC or amino acid analysis and the Bartlett inorganic phosphorous assay. Size distributions were measured using a Horiba LA920 and through visual estimations from scanning electron micrographs. Release kinetics were measured by dispersing 10-20 mg of formulation in 100 mM Tris buffer, sample the supernatant over time and quantifying the protein concentration by reverse phase HPLC.
  • mice Groups of seven (7) C57B1/6 were immunized as described in Table 8.1. Control groups of mice included na ⁇ ve, Mtb8.4 protein alone, Mtb8.4-DNA, and Mtb8.4 protein-microspheres. There were five test groups for each adjuvant, MPL and 529, which covered the various combinations of reagents. The dose of Mtb8.4 protein ⁇ was 5 ⁇ g. The adjuvant target doses were 5 ⁇ g per mouse for MPL or 529. However, the actual amount of adjuvant adn inistered was determined and set by the co-encapsulated
  • mice receiving the Mtb8.4-MPL co- encapsulated and Mtb8.4-529 co-encapsulated microspheres were 4.0 and 6.5 ⁇ g per mouse, respectively.
  • all groups receiving MPL received 4.0 ⁇ g per mouse and all groups receiving 529 received 6.5 ⁇ g per mouse.
  • mice All protein formulations were administered by the intradermal route at the base of the tail, while DNA was adniinistered intramuscularly. Three or four mice from each group were harvested two weeks after the primary immunization, with their spleens and sera collected and pooled for evaluation. The remaining three or four mice per group were boosted three weeks after the primary immunization and were harvested two weeks later.
  • Spleen cells were used in a CTL assay, an ICC assay for CD8+ and CD4+ T-cell responses, and for IFN-gamma. Sera were used to measure Mtb8.4 specific antibodies. These methods are the same as those used in Examples 1-7 above.
  • Microsphere Characterization The results of the microsphere in vitro physico-chemical analysis are shown in Table 2.
  • the Mtb8.4 protein core-loadings for the protein- microspheres (a), protein-MPL co-encapsulated microspheres (d), and protein-529 co- encapsulated microspheres (e) were similar and ranged from 0.62%-0.87%.
  • the MPL core-loadings for the MPL-microspheres (b) and the protein-MPL co-encapsulated microspheres (d) were 0.64% and 0.70%, respectively, while the loadings of the 529- microspheres (c) and the protein-529 co-encapsulated microspheres (e) were 0.71% and 0.80%o, respectively.
  • microspheres of this set were of similar size, with diameters of approximately 1 ⁇ m.
  • Table 2 also shows that the amount of protein released at the 2- hour time point was 3% for the protein microspheres and 17% and 21% for the protein- MPL and protein-529 co-encapsulated microspheres.
  • FIGS 15A-D The CD 8+ and CD4+ T-cell response results from the ICCS assays performed on spleen cells harvested after only one immunization are shown in Figures 15A-D.
  • Figures 15A and 15B represent the Mtb8.4 specific CD8 and CD4 T-cell responses for the MPL and control groups while Figures 15C-D represent the results for the 529 and control groups. All four figures show that the strongest CD8 and strongest CD4 T-cell responses were generated by the protein-adjuvant co-encapsulated microspheres with either MPL or 529. For both CD8 and CD4 T-cell responses, the protein-MPL co-encapsulated microspheres elicited stronger responses than did the protein-529 co-encapsulated microspheres.
  • FIG. 15A-D show that adjuvant-microspheres admixed with either protein alone (groups F and K) or with protein-microspheres (groups H and M) enhances both CD8 and CD4 T-cell responses above those generated by adjuvant formulated in the — AF lipid formulation (groups E, J, G, and L). That is, adjuvant-microspheres is an effective adjuvant formulation for both naked protein and for protein-microspheres using both MPL and 529.
  • IFN- ⁇ Results The IFN- ⁇ release from spleen cells harvested two-weeks after the primary irnrnunization are shown in Figure 16A (MPL and control groups) and 16B (529 and control groups).
  • Figures 16A-B show that, as with the CD8 and CD4 T-cell responses, the strongest IFN- ⁇ responses are elicited by the protein-MPL and protein- 529 co-encapsulated microspheres, with the protein-MPL co-encapsulated microsphere formulation again eliciting the stronger of the two responses.
  • IgGl and IgG2b Antibody Responses IgGl and IgG2b antibody responses measured from sera obtained two-weeks after the secondary immunization are shown in Figures 17A-B for the control groups and those receiving MPL, and in Figures 17C-D for the control groups and those receiving 529. Responses shown are the OD measured at the 16000:1 dilution for IgGl and 4000:1 dilution for IgG2b.
  • Figures 17A and 17C shown that the strongest IgGl responses were obtained for the groups receiving protein encapsulated in microspheres (groups G, H, I, L, M, and N).
  • protein-adjuvant co-encapsulation can be the most effective vaccine formulation for eliciting comprehensive immune responses, including CD 8 T- cell responses, CTL, CD4 T-cell responses, IFN- ⁇ , and IgGl and IgG2b antibody responses.
  • Co-encapsulation can be effective with both MPL, as shown in the previous examples, as well as with RC529, a synthetic AGP. Based on these results, it would be expected that other synthetic adjuvants would also be effective in a microsphere co- encapsulated formulation.
  • MPL is a slightly better adjuvant than 529 for co-encapsulating in microspheres.
  • adjuvant-microspheres are an effective formulation of adjuvants. This was shown for both MPL and 529. In comparison with — AF Liposomal adjuvant formulations, adjuvant-microspheres performed as well if not better at enhancing immune responses. Development and optimization of the adjuvant- microsphere formulation is promising for creating the most effective vaccine adjuvant formulation.
  • microspheres were made using a double-emulsion technique, and compared to co-encapsulated microspheres that were prepared using single-emulsion techniques.
  • the example demonstrates an alternative, and more manufacturing friendly way, to apply HIP that produces effective microspheres.
  • an aqueous protein solution is used as the inner aqueous phase in the double emulsion process with the HIP agent in the solvent. Presumably the protein is extracted into the solvent during the primary emulsion step.
  • Mtb8.4-MPL co-encapsulated microspheres were prepared using three different techniques but with several features in common. That is, all three formulations used 3 mg of Mtb8.4 protein, 3 mg of MPL® adjuvant, 300 mg of RG502H polymer, 400 ml of 5% PVA as the process media, and utilized a Silverson mixer to prepare the microspheres with a mixing speed of 9000 rpm.
  • the first microsphere formulation, lot #MJ102 was prepared as described in examples 1, 6 and 7.
  • Mtb8.4 protein was extracted from an aqueous solution into a docusate sodium- dichloromethane (DCM) solution via hydrophobic ion pairing.
  • DCM docusate sodium- dichloromethane
  • the aqueous solution was then discarded.
  • Polymer and MPL® adjuvant were added to the DCM and microspheres were prepared.
  • the second formulation, lot #MJ107 utilized a modified solvent system in order to solubilize the protein in the organic phase without using HIP and/or docusate sodium.
  • Mtb8.4 by itself is insoluble in DCM. That is, Mtb8.4 was lyophilized from an aqueous solution at acidic pH and dissolved in dimethyl sulfoxide (DMSO) to which an equal volume of DCM was added. Polymer and MPL® adjuvant were then dissolved in the solvent phase and microspheres were prepared.
  • the third formulation, lot #MJ108 utilized a variation on the double emulsion technique.
  • the internal aqueous phase was a 1.0 ml aqueous solution of Mtb8.4 protein at acidic pH, as with the extraction for MJ102.
  • the organic phase was DCM containing approximately 8 mg of docusate sodium, as with the extraction for MJ102, and the polymer and MPL® adjuvant.
  • the primary emulsion was formed by vigorously mixing the protein solution in the solvent phase using a vortex. Presumably the protein was extracted into the organic phase via hydrophobic ion pairing, as with MJ102. However this technique is simpler in that the aqueous phase does not need to be separated and discarded, a cumbersome aspect of the MJ102 process. Microspheres were then prepared using the primary emulsion as described above.
  • Microsphere Characterization The protein and adjuvant contents of the microspheres were determined by HPLC or amino acid analysis and the Bartlett inorganic phosphorous assay. Size distributions were measured using a Horiba LA920 and through visual estimations from scanning electron micrographs. Release kinetics were measured by dispersing 10-20 mg of formulation in 100 mM Tris buffer, sampling the supernatant over time, and quantifying the protein concentration by reverse phase HPLC.
  • mice Groups of seven (7) C57B1/6 were immunized with 5 ⁇ g of encapsulated Mtb8.4 protein per mouse.
  • the target dose of MPL® adjuvant was 5 ⁇ g per mouse.
  • the actual dosings were 4.1, 4.3, and 6.4 ⁇ g per mouse for MJ102, MJ107, and MJ108, respectively (Table 3).
  • Control groups of mice include na ⁇ ve, Mtb8.4 protein plus MPL-AF, protein plus the -AF vehicle (lipids in water), and Mfb8.4-DNA. All protein formulations were administered by the intradermal route while DNA was administered intramuscularly.
  • Three or four mice from each group were harvested two weeks after priming, with their spleens and sera collected and pooled for evaluation. The remaining three or four mice per group were boosted three weeks after priming and harvested two weeks later.
  • Microsphere Characterization The protein and MPL® contents ("core-loading,” abbreviated as "CL") and encapsulation efficiencies are listed in Table 3. The encapsulation efficiencies for the protein were similar and reasonable, ranging from 64- 76% for MJ102, MJ107, and MJ108. The MPL® adjuvant encapsulation efficiencies were also similar and reasonable in value, ranging from 62-79%. The adjuvant-to-antigen ratios were also all close to unity, ranging from 0.81 to 1.28.
  • the median particle diameters and the initial protein release kinetic data for these three formulations are shown in Table 4.
  • the median diameters for these formulations are between 1 and 2.6 ⁇ g, well within the size range desired for optimal phagocytosis of microspheres (i.e., ⁇ 1-10 ⁇ m).
  • Table 4 also shows that the two formulations containing AOT, MJ102 and MJ108, exhibit significantly lower initial release kinetics than MJ107. That is, 78% of the encapsulated protein for MJ107 is released within 2 hours while only approximately 20% of the protein is released from MJ102 and MJ107.
  • CTL responses measured two weeks after a single immunization are shown in Figure 18.
  • Mice receiving Mtb8.4 protein plus MPL® adjuvant exhibited no significant specific CTL responses.
  • na ⁇ ve mice and mice receiving protein plus the — AF vehicle (lipids) failed to elicit specific CTL responses.
  • the Mtb8.4 protein-MPL co-encapsulated formulation that previously was proven effective (See Examples 1, 6, 7, and 8), MJ102, again successfully elicited CTLs.
  • co- encapsulated microspheres prepared using the double emulsion technique, MJ108 elicited a CTL response similar in strength.
  • MJ107 the co-encapsulated formulation with nearly 80% release at 2 hours, did not elicit a strong CTL response at this time-point in this experiment.
  • IFN-gamma Release from spleen cell cultures measured from mice receiving either a primary immunization or a primary and a secondary immunizations are shown in Figure 19.
  • Figure 19 shows that essentially no IFN-gamma was elicited in mice receiving protein plus MPL® adjuvant, protein plus -AF vehicle, or na ⁇ ve mice. Mice receiving DNA elicited IFN-gamma responses barely above background.
  • MJ102 and MJ108 microspheres both elicited strong and comparable IFN-gamma responses in mice receiving either one or two imrnunizations.
  • MJ107 microspheres elicited lower IFN-gamma than the other two microsphere formulations having lower initial release kinetics but levels above background and comparable to those in the DNA group.
  • Figures 20 and 21 show the Mtb8.4 specific IgG2b and IgGl antibody responses elicited in mice, respectively.
  • Figure 20 shows that the three microsphere formulations elicited the strongest IgG2b responses. Protein plus MPL® adjuvant and M ⁇ 8.4-DNA elicited lower levels of IgG2b than did the microspheres. As with the CTL and IFN-gamma responses, MJ102 and MJ108 elicited stronger responses than MJ107.
  • Figure 21 shows that the three microsphere formulations elicited the strongest IgGl specific antibody responses. Protein plus MPL® adjuvant and Mtb8.4-DNA elicited lower levels of IgGl than did the microspheres. In contrast to the other immune response measurements, the IgGl responses for the three microsphere formulations were all comparable.
  • 72f is a fusion of three polypeptides: RA12, TbH9, and RA35.
  • the example shows that: (1) recombinant 72f (r72f) protein encapsulated in microspheres can elicit strong CD4+ and CD8+ T-cell responses, CTL and antibody responses; (2) co-encapsulation of r72f and adjuvant (MPL) elicits stronger immune responses than r72f-microsperes without adjuvant; (3) double emulsion and single emulsion formulations both elicit the strongest immune responses; and (4) CD4+ T-cell responses (Elispot) elicited by the best microspheres are dramatically stronger than those elicited by protein plus AS-2 (MPL and saponin), protein plus MPL, and protein alone.
  • a series of initial PLG microsphere formulations of the M. tuberculosis fusion protein 72f were prepared and evaluated in vivo.
  • the formulation methods and materials were chosen in order to vary the interactions of the protein with itself, polymer, the solvents etc. during microsphere formation and in the final product. The differences are designed to produce different microsphere properties in terms of in vitro characterization and, moreover, in vivo evaluation of their ability to generate comprehensive antigen specific immune responses.
  • Two of these formulations had protein and MPL® adjuvant co- encapsulated. Immune responses were measured for each of the three constituents of the 72f fusion protein (see Immune Responses below).
  • Microsphere Preparation 72f protein microspheres were prepared using single and double emulsion techniques (Table 5). All formulations described in Table 1 had 300 mg of a PLG polymer, 3 mg of 72f protein, 10 ml of organic solvent (Table 5), and were emulsified using a Silverson mixer at 9000 rpm to produce microspheres.
  • Microsphere Characterization The protein and adjuvant contents of the microspheres were determined by amino acid analysis and the Bartlett inorganic phosphorous assay. Size distributions were measured using a Horiba LA920 and tiirough visual estimations from scanning electron micrographs.
  • mice Groups of three C57BL/6 mice were immunized twice, three weeks apart with 10 ⁇ g of encapsulated 72f protein per mouse at the base of the tail (i.e., ID). Spleens and sera were harvested from the mice two weeks post second immunization for evaluation of immune response generation.
  • the target dose of MPL® adjuvant was 10 ⁇ g per mouse.
  • Control groups included na ⁇ ve mice, protein alone (10 ⁇ g), protein plus AS- 2 (MPL® and saponin) in an oil-in-water emulsion, and protein plus MPL®-SE adjuvant.
  • Spleen cells were used in Elispot and CTL assays. Cells were stimulated with TbH9 protein, RA12 protein, RA35 protein, and a CD8 10 amino acid Db epitope to RA12 for the Elispot assay. Cells were stimulated with EL4 cells transduced with Ral2 protein for the CTL assay. Antigen specific ELISAs were used to measure antibodies to TbH9 protein, RA12 protein, and RA35 protein in sera.
  • the protein and MPL® contents (“core-loading,” or “CL”) are listed in Table 6.
  • the protein core-loadings were similar, ranging from 0.63% to 1.35%.
  • the MPL® adjuvant core-loadings for AM123 and AM124 were 0.68% and 0.93%, resulting in the administration of approximately twice as much adjuvant for AM124 than for AM123, given a fixed protein dose (i.e., 10 ⁇ g).
  • Table 6 shows that the sizes of the microspheres were also similar at approximately 1 ⁇ m in diameter.
  • Elispot Assay The results of the Elispot assay are based on triplicates obtained from the pooled spleen cells of three mice. The numbers indicated represent the number of IFN- ⁇ Elispots per well. Negative controls for the assay where cells from each mouse in each group that were stimulated with medium alone. Each of the medium stimulated wells had few ( ⁇ 15) positive spots. In contrast, cells stimulated with TbH9 recombinant protein (10 ⁇ g/ml) showed positive but varied responses between groups. That is, na ⁇ ve mice ("medium" row), and mice receiving protein alone, failed to elicit a TbH9 specific positive response.
  • AMI 17 (no MPL) and AMI 23 (MPL co-encapsulation) clearly demonstrates the dramatic enhancement in immune responses generated due to MPL co-encapsulation.
  • AM120 (no MPL) responses are already maximal, no difference can be seen with AM124 (MPL co-encapsulation).
  • No Ra35 nor RA12 specific responses were observed, relative to na ⁇ ve mice.
  • the strongest responses to the Ral2 CD8+ T cell epitope (peptide #86-95) were again observed with microspheres. For this read out, the responses were fairly uniform for six of the eight formulations (AM 116, AMI 17 AMI 19, AM120, and AM123) while AMI 18 and AM124 exhibited slightly lower responses.
  • protein microspheres generated the strongest CD4+ T cell responses to TbH9 as well as CD8+ T cell responses to the Ral2 epitope. These responses were far stronger than those of protein alone and stronger than those elicited by MPL and AS-2 adjuvant systems.
  • CTL Responses Secondary CTL responses were measured against Ral2 two weeks after the second irnmunizations. Mice receiving 72f protein plus MPL® adjuvant exhibited no significant specific CTL responses. No specific lysis was observed for na ⁇ ve mice and mice receiving protein alone. Protein plus AS-2 generated CTL responses in 3/3 mice, with moderate to high levels of background. All of the protein-microsphere formulations elicited CTL responses, with the sole exception of AMI 18. The strongest, most consistent CTL responses were to AM123, AMI 16, AMI 17 and AMI 19. Comparison of AMI 17 (no MPL) with AMI 23 (MPL co-encapsulation) again demonstrates the substantive enhancement of immune responses generation by co- encapsulating MPL. In short, protein microspheres clearly generated stronger CTL responses than protein alone and protein plus MPL® adjuvant.
  • IgGl responses against both TbH9 and Ra35 were similar for the microsphere formulations and for protein plus AS-2, while responses to protein alone and protein plus MPL (for Ra35) were lower.
  • Minimal IgG2a was elicited against TbH9 and Ra35.
  • ICD- protein microspheres can produce effective tumor protection.
  • different polymers, additives and tecl niques were utilized to produce microspheres with different properties, as measured either in vitro or in vivo.
  • these approaches were designed to vary the interactions of the protein with itself, with the polymer, with an additive, and to vary the interactions of the solvents, polymer, stabilizers and water with each other, both during the manufacturing process, as well as in the final microsphere product. None of these formulation contained adjuvant. These four formulations were evaluated in a tumor protection model.
  • Microsphere Preparation Four different ICD protein microsphere formulations were prepared, characterized, and evaluated in a tumor protection model. These formulations had several features in common. All three formulations used 2.5 mg of ICD protein, 300 mg of PLG polymer, 5% PVA as the process media, and a Silverson mixer to prepare the microspheres. The formulation parametric variations for these microspheres are summarized in Table 7. These included single emulsion and double emulsion techniques, polymer end-group type (carboxylic acid "H" vs.
  • ester end groups polymer end group frequency (i.e., polymer molecular weight: ⁇ 10k and ⁇ 40K), the solvent system used (DCM and DMC:DMSO (1:3.3)), the process media volume, the mixing speed used (7000 and 9000 rpm), and the addition of an additive (ethyl stearate).
  • Microsphere Characterization The protein contents of the microspheres were determined by amino acid analysis. Size distributions were measured using a Horiba LA920 and through visual estimations from scanning electron micrographs.
  • Immunizations Groups of eight (8) C57B1/6 mice were immunized twice, three weeks apart, with 25 ⁇ g of encapsulated ICD protein per mouse. Control groups received 25 ⁇ g of ICD formulated in Montanide, an adjuvant previously determined to perform well with this system, ICD-DNA, and na ⁇ ve mice. Protein formulations were administered by the intradermal route while DNA was administered intramuscularly.
  • Tumor Challenge Two weeks after receiving the second immunizations mice were challenged with EL4-Her-2/neu tumor cells. Tumor sizes were measured periodically over six weeks.
  • Microsphere Characterization The protein and contents ("core-loading," abbreviated CL) and microsphere diameters for AM049, AM050, AM051, and AM051 ICD- microspheres are listed in Table 8. Table 8 shows that these microsphere formulations had similar core-loadings, ranging from 0.96% to 1.24%, and were of similar sizes. Table 8: ICD Formulation Characterization
  • Figures 23-29 show the results of the tumor protection experiment.
  • Figure 22 shows the tumor progression in na ⁇ ve mice. Six of eight mice had tumor growth shortly after tumor implantation with seven of eight mice exhibiting significant tumor growth by the end of the experiment.
  • Figures 23 and 24 show tumor growth in the positive control groups that received ICD protein in Montanide and ICD-DNA, respectively.
  • Figure 23 shows that ICD formulated in Montanide adjuvant, an adjuvant that has previously been found to be effective in this tumor model, exhibited enhanced protection relative to na ⁇ ve mice.
  • week 6 3/8 mice in the Montanide group had significant tumor growth.
  • ICD-DNA the most consistent positive control in previous experiments, resulted in significant tumor protection (Figure 24). No mice receiving the DNA immunizations had measurable tumor growth until nearly the end of the experiment, at which time one mouse was found to be growing tumor.
  • ICD- protein microsphere lot AM049 Figure 25
  • AM051 Figure 27
  • ICD protein microsphere lot AM050 produced significant protection ( Figure 26).
  • week 6 only 2/8 mice had significant tumor growth, a result comparable to if not slightly better than the Montanide adjuvant group.
  • ICD protein microsphere lot AM052 (Figure 28) appears to have produced the strongest and most consistent protection results for any of the protein formulations.
  • week 6 only 1/8 mice had significant tumor growth with a second mouse having just begun to show tumor growth.
  • the background tumor sizes measured for the first four weeks was extremely low, similar to that produced by the DNA immunizations ( Figure 25).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Selon l'invention, un appariement ionique hydrophobe (HIP) est appliqué pour solubiliser des protéines et/ou des adjuvants dans un milieu organique. Un polymère est co-solubilisé dans le milieu et des microsphères encapsulant la protéine et/ou l'adjuvant peuvent être produites par un unique procédé d'émulsion. Les microsphères produites grâce à ce procédé fournissent une faible salve initiale de protéine puis une libération progressive au cours du temps, et déclenchent une réaction immunitaire forte et complète. L'invention a également pour objet des compositions une protéine et un adjuvant co-encapsulés dans des microsphères.
PCT/US2002/021758 2001-07-10 2002-07-10 Compositions et procedes destines a l'administration de proteines et d'adjuvants encapsules dans des microspheres WO2003005952A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002354644A AU2002354644C1 (en) 2001-07-10 2002-07-10 Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
JP2003511761A JP2005514326A (ja) 2001-07-10 2002-07-10 ミクロスフェア中に封入されたタンパク質およびアジュバントを送達するための組成物および方法
EP02752243A EP1417236A4 (fr) 2001-07-10 2002-07-10 Compositions et procedes destines a l'administration de proteines et d'adjuvants encapsules dans des microspheres
NZ530315A NZ530315A (en) 2001-07-10 2002-07-10 Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
CA002452382A CA2452382A1 (fr) 2001-07-10 2002-07-10 Compositions et procedes destines a l'administration de proteines et d'adjuvants encapsules dans des microspheres

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30459001P 2001-07-10 2001-07-10
US60/304,590 2001-07-10
US34601301P 2001-11-09 2001-11-09
US60/346,013 2001-11-09

Publications (2)

Publication Number Publication Date
WO2003005952A2 true WO2003005952A2 (fr) 2003-01-23
WO2003005952A3 WO2003005952A3 (fr) 2003-05-30

Family

ID=26974112

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/021758 WO2003005952A2 (fr) 2001-07-10 2002-07-10 Compositions et procedes destines a l'administration de proteines et d'adjuvants encapsules dans des microspheres

Country Status (7)

Country Link
US (2) US20030108565A1 (fr)
EP (2) EP2241309A3 (fr)
JP (1) JP2005514326A (fr)
AU (1) AU2002354644C1 (fr)
CA (1) CA2452382A1 (fr)
NZ (1) NZ530315A (fr)
WO (1) WO2003005952A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087260A1 (fr) * 2004-03-04 2005-09-22 Corixa Corporation Formulations d'immunostimulants en microspheres et de polypeptide wt1 en co-encapsulation, et procedes correspondants
WO2009135853A2 (fr) * 2008-05-06 2009-11-12 Glaxo Group Limited Encapsulation d'agents actifs biologiquement
WO2009135855A2 (fr) * 2008-05-06 2009-11-12 Glaxo Group Limited Encapsulation d'agents biologiquement actifs
WO2014141127A1 (fr) * 2013-03-15 2014-09-18 Glaxosmithkline Biologicals S.A. Composition contenant des dérivés d'aminoalkyl-glucosaminide phosphate en solution tampon et son utilisation pour améliorer une réponse immunitaire
EP2994162A1 (fr) * 2013-05-08 2016-03-16 Protatek International Inc. Vaccin pour pcv2 et mycoplasme

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3492671B2 (ja) * 2002-04-18 2004-02-03 理化学研究所 免疫アジュバント
US20050186183A1 (en) * 2003-12-08 2005-08-25 Deangelo Joseph Stabilized products, processes and devices for preparing same
EP1703409A1 (fr) * 2004-07-21 2006-09-20 Sony Corporation Dispositif de traitement du contenu, méthode de traitement du contenu et programme informatique
EP1885186B1 (fr) * 2005-06-01 2015-09-02 California Institute Of Technology Procede permettant le transfert cible de genes au moyen de vecteurs viraux
US20060275777A1 (en) * 2005-06-03 2006-12-07 Waelti Ernst R Novel strategies for protein vaccines
PL2162149T3 (pl) 2007-06-01 2014-04-30 Henry M Jackson Found Advancement Military Medicine Inc Szczepionka do zapobiegania nawrotowi raka sutka
US8815253B2 (en) * 2007-12-07 2014-08-26 Novartis Ag Compositions for inducing immune responses
CA2721307A1 (fr) * 2008-05-06 2009-11-12 Glaxo Group Limited Encapsulation d'agents actifs biologiquement
CN107252482A (zh) 2009-05-27 2017-10-17 西莱克塔生物科技公司 具有不同释放速率的纳米载体加工组分
US20110293701A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Multivalent synthetic nanocarrier vaccines
CN109172819A (zh) 2011-07-29 2019-01-11 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
CN104771362B (zh) * 2014-09-03 2018-01-02 沈阳药科大学 一种克拉霉素离子对脂质微球注射液及其制备方法
WO2022109279A1 (fr) * 2020-11-19 2022-05-27 Phosphorex, Inc. Appariement d'ions (ip) pour la production de microparticules

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
NL8403195A (nl) * 1984-10-19 1986-05-16 Nederlanden Staat Immunogene complexen en vaccins die deze bevatten.
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
AU5741590A (en) * 1989-05-04 1990-11-29 Southern Research Institute Improved encapsulation process and products therefrom
US5149543A (en) * 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
ES2143716T3 (es) 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5928647A (en) 1993-01-11 1999-07-27 Dana-Farber Cancer Institute Inducing cytotoxic T lymphocyte responses
US5562909A (en) * 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
DK0724432T3 (da) * 1993-10-22 2003-01-27 Genentech Inc Fremgangsmåder og præparater til mikroindkapsling af antigener til brug som vacciner
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167377B2 (fr) 1994-07-15 2012-08-08 University of Iowa Research Foundation Oliogonucléotides immunomodulateurs
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
AU6330896A (en) * 1995-06-07 1996-12-30 Governors Of The University Of Alberta, The A method for eliciting a th1-specific immune response
US5919463A (en) * 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
US6406704B1 (en) * 1996-08-29 2002-06-18 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
FR2769854B1 (fr) * 1997-10-21 2000-03-31 Prographarm Lab Nouveau procede d'obtention de microspheres et les produits ainsi realises
US6114491A (en) * 1997-12-19 2000-09-05 Georgia-Pacific Resins, Inc. Cyclic urea-formaldehyde prepolymer for use in phenol-formaldehyde and melamine-formaldehyde resin-based binders
WO1999055310A1 (fr) * 1998-04-27 1999-11-04 Altus Biologics Inc. Cristaux de proteines stabilisees, formulations renfermant lesdits cristaux et leurs procedes de fabrication
JP2002506876A (ja) * 1998-03-18 2002-03-05 ユニバーシティ テクノロジー コーポレーション 非晶質ポリマーを含む持続放出性組成物
SE9801288D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
US6261573B1 (en) * 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
CN1201004C (zh) 1999-01-29 2005-05-11 考丽克萨有限公司 HER－2/neu融合蛋白
AU755502C (en) * 1999-03-24 2003-08-14 Secretary Of State For Defence, The Immunostimulants
EP1246597B1 (fr) * 1999-08-03 2015-01-14 The Ohio State University Polypeptides et polynucleotides ameliorant la reactivite immunitaire a la proteine her-2
EP1299087A1 (fr) 2000-07-07 2003-04-09 Corixa Corporation Microspheres et adjuvants utilises pour l'administration de vaccins a base d'adn
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COLER R.N. ET AL.: 'Vaccination with the T cell antigen Mtb 8.4 protects against challenge with mycobacterium tuberculosis' JOURNAL OF IMMUNOLOGY vol. 166, May 2001, pages 6227 - 6235, XP002961490 *
DILLON D.C. ET AL.: 'Molecular characterization and human T-cell responses to a memeber of a novel mycobacterium tuberculosis mtb39 gene family' INFECTION AND IMMUNITY vol. 67, no. 6, June 1999, pages 2941 - 2950, XP002143391 *
DISIS M.L. ET AL.: 'Generation of immunity of the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine' CLINICAL CANCER RESEARCH vol. 5, June 1999, pages 1289 - 1297, XP000914565 *
See also references of EP1417236A2 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087260A1 (fr) * 2004-03-04 2005-09-22 Corixa Corporation Formulations d'immunostimulants en microspheres et de polypeptide wt1 en co-encapsulation, et procedes correspondants
EP2441447A1 (fr) * 2008-05-06 2012-04-18 Glaxo Group Limited Encapsulation d agents actifs biologiquement
WO2009135855A2 (fr) * 2008-05-06 2009-11-12 Glaxo Group Limited Encapsulation d'agents biologiquement actifs
WO2009135855A3 (fr) * 2008-05-06 2011-01-27 Glaxo Group Limited Encapsulation d'agents biologiquement actifs
US20110059142A1 (en) * 2008-05-06 2011-03-10 Irene Papanicolaou Encapsulation of biologically active agents
WO2009135853A3 (fr) * 2008-05-06 2011-05-12 Glaxo Group Limited Encapsulation d'agents actifs biologiquement
WO2009135853A2 (fr) * 2008-05-06 2009-11-12 Glaxo Group Limited Encapsulation d'agents actifs biologiquement
WO2014141127A1 (fr) * 2013-03-15 2014-09-18 Glaxosmithkline Biologicals S.A. Composition contenant des dérivés d'aminoalkyl-glucosaminide phosphate en solution tampon et son utilisation pour améliorer une réponse immunitaire
BE1021939B1 (fr) * 2013-03-15 2016-01-27 Glaxosmithkline Biologicals S.A. Composition pour des composes aminoalkylglucosaminide phosphate tamponnes et son utilisation.
US9827260B2 (en) 2013-03-15 2017-11-28 Glaxosmithkline Biologicals Sa Composition for buffered aminoalkyl glucosaminide phosphate compounds and its use for enhancing an immune response
EP2994162A1 (fr) * 2013-05-08 2016-03-16 Protatek International Inc. Vaccin pour pcv2 et mycoplasme
EP2994162A4 (fr) * 2013-05-08 2016-12-21 Protatek Int Inc Vaccin pour pcv2 et mycoplasme
US9649370B2 (en) 2013-05-08 2017-05-16 Protatek International, Inc. Vaccine for PCV2 and mycoplasma
US9956279B2 (en) 2013-05-08 2018-05-01 Protatek International, Inc. Vaccine for PCV2 and mycoplasma

Also Published As

Publication number Publication date
EP2241309A3 (fr) 2012-12-26
EP1417236A2 (fr) 2004-05-12
AU2002354644B2 (en) 2007-10-04
EP2241309A2 (fr) 2010-10-20
JP2005514326A (ja) 2005-05-19
AU2002354644C1 (en) 2009-04-30
CA2452382A1 (fr) 2003-01-23
EP1417236A4 (fr) 2010-03-17
US20070148254A1 (en) 2007-06-28
WO2003005952A3 (fr) 2003-05-30
NZ530315A (en) 2007-01-26
US20030108565A1 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
US20070148254A1 (en) Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
AU2002354644A1 (en) Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
EP1572074B1 (fr) Systeme d'administration d'immunogene synthetique stabilise
CA2420621C (fr) Compositions de microparticules et procede de fabrication desdites compositions
O'Hagan et al. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles
EP0724431B1 (fr) Procedes et compositions de microencapsulation d'adjuvants
US8541023B2 (en) Immunogenic compositions containing phospholipid
AU2001294898A1 (en) Microparticle compositions and methods for the manufacture thereof
JP2002537102A (ja) 吸着された高分子および微粒子を有するミクロエマルジョン
US20040009941A1 (en) Microspheres and adjuvants for DNA vaccine delivery
CA2731995C (fr) Procede d'induction d'une reponse immunitaire a mediation cellulaire et formulations parenterales de vaccins associees
US20020146828A1 (en) Microparticles and methods for delivery of recombinant viral vaccines
O'Hagan Recent advances in immunological adjuvants: the development of particulate antigen delivery systems
WO2002062319A2 (fr) Administration sous forme de microspheres de peptides de mucine
Kirby Formulation and characterisation of an effective particulate delivery vehicle for the novel sub-unit vaccine antigen, Ag85B-ESAT-6
Rhodes Overview: Recent Advances in Vaccine Adjuvants
PT1585542E (pt) Composições imunogénicas contendo fosfolípido

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002354644

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 530315

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2452382

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003511761

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002752243

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002752243

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642